The BDP Working Group at pursues basic and applied social, behavioral, decision, and engineering science, focusing on policy-related problems in the areas of Environment, Communication, Decision Science, Energy, and Health.
Featured Paper: The FDA's Usage of "Breakthrough" Language
New research featuring BDP researchers Tamar Krishnamurti (pictured) and Baruch Fischhoff
This randomized trial explores why FDA press releases with neutral terms and that routinely explain the limited evidence supporting accelerating approval might help consumers make more accurate judgments about drugs with breakthrough designation.
Read the paper: Krishnamurti, T., Woloshin, S., Schwartz, L. M., & Fischhoff, B. (2015). A Randomized Trial Testing US Food and Drug Administration “Breakthrough” Language. JAMA Internal Medicine, 175 (11):1856-1858.
Read the article's press coverage here.